Deals19 Dec 2025, 11:36 am
Pfizer Ltd Enters Exclusive Supply & Marketing Agreement with Cipla Limited for Corex Dx, Corex LS, Dolonex, and Neksium Brands
AI Summary
Pfizer Ltd has entered into an exclusive Supply and Marketing Agreement with Cipla Limited for marketing and distribution of four brands, namely Corex Dx, Corex LS, Dolonex, and Neksium for an initial period of 5 years within the territory of India. This partnership aims to make Pfizer’s medicines widely available across India by combining its well-established portfolio with Cipla’s deep market reach. The agreement is expected to significantly enhance availability of key brands for patients across the country.
Key Highlights
- Pfizer Ltd has entered into an exclusive Supply and Marketing Agreement with Cipla Limited for Corex Dx, Corex LS, Dolonex, and Neksium brands.
- The agreement is for an initial period of 5 years within the territory of India.
- This partnership aims to make Pfizer’s medicines widely available across India.
- Cipla has an extensive customer understanding, distribution reach and network.
- The agreement is expected to significantly enhance availability of key brands for patients across the country.